Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasiglucagon Autoinjector for Hypoglycemia Rescue in T1DM
NCT03688711Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypoglycemia comparing Dasiglucagon with Placebo (2 arms). Primary endpoint: Time to Plasma Glucose Recovery. Started Nov 2018; status: completed.
02
Drugs
dasiglucagon
03
Conditions
hypoglycemia
Beyond the preview
Go deeper on NCT03688711.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03688711.